A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection

Neurology

Volumn 54, Issue 5, 2000, Pages 1080-1088

  McArthur, J C ^a,p   Yiannoutsos, C ^b   Simpson, D M ^c   Adornato, B T ^p   Singer, E J ^d   Hollander, H ^e   Marra, C ^f   Rubin, M ^g   Cohen, B A ^h   Tucker, T ⁱ   Navia, B A ^j   Schifitto, G ^p   Katzenstein, D ^p   Rask, C ^k   Zaborski, L ^b   Smith, M E ^l   Shriver, S ^m   Millar, L ⁿ   Clifford, D B ^o  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k GENENTECH INC   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m AIDS Clinical Trials Group Operations Center   (United States)

ⁿ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^o WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p NONE

more..

Author keywords

Analgesic; Dideoxynucleoside; HIV associated sensory neuropathy; Nerve growth factor; Pain

Indexed keywords

ANALGESIC AGENT; DIDANOSINE; PLACEBO; RECOMBINANT NERVE GROWTH FACTOR; STAVUDINE; ZALCITABINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; TREATMENT OUTCOME;

EID: 0034646215     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.5.1080     Document Type: Article

References (41)

1. Cornblath DR, McArthur JC. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988;38:794-796.
2. So YT, Holtzman DM, Abrams DI, Olney RK. Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. Arch Neurol 1988;45:945-948.
3. Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1 related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology 1994;44:1892-1900.
4. Blum AS, Dal Pan GJ, Feinberg J, et al. Low dose zalcitabine (ddC)-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 1996;46:999-1003.
5. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syn 1995;9:153-161.
6. Kieburtz K, Yiannoutsos CP, Simpson D, the AIDS Clinical Trials Group Protocol 242 Study Team. A double blind, randomized clinical trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Ann Neurol 1997;42:429. Abstract.
7. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. Neurology 1996;47:1254-1259.
8. Griffin JW, Crawford TO, McArthur JC. Peripheral neuropathies associated with HIV infection. In: Gendelman HE, Lipton SA, Epstein L, Swindells S, eds. The neurology of AIDS. New York: Chapman & Hall, 1998:275-291.
9. Riaz SS, Tomlinson DR. Neurotrophic factors in peripheral neuropathies: pharmacological strategies. Prog Neurobiol 1996;49:125-143.
10. Mearow KM, Kril Y, Diamond J. Increased NGF mRNA expression in denervated rat skin. NeuroReport 1993;4:351-354.
11. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162.
12. Doubleday B, Robinson PP. The role of nerve growth factor in collateral reinnervation by cutaneous C-fibers in the rat. Brain Res 1992;593:179-184.
13. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992;31:76-80.
14. Apfel SC, Kessler JA, Adornato BT, et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. Neurology 1998;51:695-702.
15. Janssen RS, Cornblath DR, Epstein LG, et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-785.
16. Max MB, Lunch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
17. Gracely RH, McGrath P, Dubner R. Ratio scales of sensory and affective verbal pain descriptors. Pain 1978;5:5-18.
18. Dyck PJ, Zimmerman I, Gillen DA, Johnson D, Karnes JL, O'Brien PC. Cool, warm, and heat-pain detection thresholds: testing methods and inferences about anatomic distribution of receptors. Neurology 1993;43:1500-1508.
19. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996;2:625-629.
20. Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small fiber sensory neuropathies: Clinical course and neuropathology of idiopathic cases. Ann Neurol 1998;44:47-59.
21. McCarthy BG, Hsieh S-T, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848-1855.
22. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50:1096-1121.
23. Dyck PJ, Zimmerman IR, Johnson DM, et al. A standard test of heat-pain responses using CASE IV. J Neurol Sci 1996;136: 54-63.
24. McArthur JC, Stocks A, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative range and diagnostic efficiency. Arch Neurol 1998;55:1513-1520.
25. Adornato BT, Kessler JA, Dyck PJ, Apfel S, Cornblath DR, Petty BG. Benign transient neuromyalgic response (BeTNR) of NGF: a novel physiologic reaction to human recombinant nerve growth factor (rhNGF). Neurology 1997;48(suppl 2): A118. Abstract.
26. Rask CA, Adornato B, Sanders C. Clinically relevant doses of recombinant human nerve growth factor (rhNGF) have a large margin of safety (abstract 1444). 80th Annual programme and abstracts of the annual meeting of the Endocrine Society 1998; New Orleans; June 24-27, 1988.
27. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994;36:244-246.
28. Kress M, Koltzenburg M, Reeh PW, Handwerker HO. Responsiveness and functional attributes of electrical terminals of cutaneous C-fibers in vivo and in vitro. J Neurophysiol 1992; 68:581-595.
29. Ziegler D, Mayer P, Gries FA. Evaluation of thermal, pain, and vibration sensation thresholds in newly diagnosed type 1 diabetic patients. J Neurol Neurosurg Psychiatry 1988;51: 1420-1424.
30. Dyck PJ, Winkelmann RK, Bolton CF. Quantitation of Meissner's corpuscles in hereditary neurologic disorders. Neurology 1966;16:10-17.
31. Bolton CF, Winkelmann RK, Dyck PJ. A quantitative study of Meissner's corpuscles in man. Neurology 1966;16:1-9.
32. Ridley A. Silver staining of nerve endings in human digital glabrous skin. J Anat 1969;104:41-48.
33. Kennedy WR, Wendelschafer-Crabb G. The innervation of human epidermis. J Neurosci 1993;115:184-190.
34. Karanth SS, Springall DR, Lucas S, et al. Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. J Pathol 1989;157:15-26.
35. Dalsgaard CJ, Jonsson CE, Hokfelt T, Cuello AC. Localization of substance P-immunoreactive nerve fibers in the human digital skin. Experientia 1983;39:1018-1020.
36. Stocks EA, McArthur JC, Griffin JW, Mouton PR. An unbiased method for estimation of total epidermal nerve fiber length. J Neurocytol 1996;25:637-644.
37. Holland NR, Stocks A, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology 1997;48:708-711.
38. Navarro X, Verdu E, Wendelschafer-Crabb G, Kennedy WR. Immunohistochemical study of skin reinnervation by regenerative axons. J Comp Neurol 1997;380:164-174.
39. Lauria G, McArthur JC, Hauer PE, Griffin JW, Cornblath DR. Neuropathologic alterations in diabetic truncal neuropathy. Evaluation by skin biopsy. J Neurol Neurosurg Psychiatry 1998;65:762-766.
40. Cooley TP, Kunches LM, Saunders CA, et al. Once-daily administration of 2′,3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1340-1345.
41. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-422.